Clinical Trial Update: A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind study evaluating TAK-438 (vonoprazan) at 20 mg and 40 mg for patients with proton pump inhibitor-resistant erosive esophagiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis

Drugs mentioned

• TAK-438 (vonoprazan)

Snippet

Sponsor: Takeda | Conditions: Erosive Esophagitis | Phase 3 | Status: COMPLETED